Multiple motor regions of the brain are underactive during lower limb movements in Parkinson's patients, according to a study.

Published Date: 26 Apr 2023

Parkinson's disease is a prevalent neurodegenerative condition that impairs movement. A person's gait and balance are eventually affected by the disease, which frequently starts with minor hand tremors.

Read Full News

Latest News

NeuroVoices: Christina Briscoe, MD; Emily Spelbrink, MD, PhD, on Addressing Equity Gaps in Infantile Epileptic Spasms Syndrome Marco Meglio, Christina Briscoe, MD, Emily Spelbrink, MD, PhD

A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

GLP-1 Liraglutide Displays Effectiveness as Migraine Treatment in Early-Stage Study Louie Pasculli

In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.

Fenfluramine Treatment Leads to Long-Term Improved Everyday Executive Functioning in Lennox-Gastaut Syndrome Marco Meglio

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

NeurologyLive®: Charting our 2026 Conference Coverage Louie Pasculli

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

AES Poster Shines Light on Positive Phase 3 GEMZ Study of Fenfluramine in CDKL5 Deficiency Disorder Marco Meglio

Fenfluramine shows significant seizure reduction in CDKL5 deficiency disorder, offering hope for families facing treatment-resistant epilepsy challenges.

Fenfluramine’s Safety Profile Consistent in Long-Term Extension Dravet and Lennox-Gastaut Syndrome Studies Isabella Ciccone, MPH

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

Todays Updates

Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial

Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial

Todays Updates

Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial

Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial

Latest News

A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Fenfluramine shows significant seizure reduction in CDKL5 deficiency disorder, offering hope for families facing treatment-resistant epilepsy challenges.

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

News All Time

Previewing Parkinson Disease Pipeline: Emerging Trials to Watch in 2026 Marco Meglio

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Parkinson disease that may impact care.

Previewing Expected FDA Decisions in Neurology for 2026 Marco Meglio

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

NeurologyLive® Year in Review 2025: What Trials Could Reshape Alzheimer Care? Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Alzheimer disease and dementia that may impact care.

NeurologyLive® Friday 5 — January 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 2, 2026.

Linking Exercise to Dopamine and Motor Performance in Parkinson Disease Marco Meglio

Margaret Rice, PhD, a professor in the Departments of Neurosurgery and Neuroscience at NYU Grossman School of Medicine, provided answers on recently published preclinical research relating aerobic exercise to dopamine release and coordination in PD.

NeurologyLive® Year in Review 2025: Top Interviews on the AI Takeover Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.

NeuroVoices: David A. Hafler, MD, FANA, on Understanding MS as an Autoimmune and Neurodegenerative Disease Isabella Ciccone, MPH, David A. Hafler, MD, FANA

At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.

NeurologyLive® Year in Review 2025: Top trending Migraine Trials NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.

NeurologyLive® Year in Review 2025: Spotlighting SAP Collaborations Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at our top collaborative interviews with the Strategic Alliance Partnership program in 2025.

NeurologyLive® Year in Review 2025: Most Impactful FDA Decisions Isabella Ciccone, MPH

These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.

Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment Marco Meglio

Avadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.

NeurologyLive® Year in Review 2025: Conference Coverage Recap NeurologyLive® Staff

NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

NeurologyLive® Brain Games: December 28, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on RBD as a prodromal marker for synucleinopathies!

Wnt/β-catenin in Multiple Sclerosis: A Nuanced Approach to Remyelination Kevin Chang, PharmD

In this Neuropathways piece, Kevin Chang, PharmD, explores the complexities of remyelination in multiple sclerosis and the potential of Wnt/β-catenin signaling as a therapeutic target.

This Week on NeurologyLive® — December 29, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Friday 5 — December 26, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.

Recommended News For You

Understudied mental health challenges among caregivers of cancer patients: A call for targeted support

Advanced breast cancer patients living longer thanks to improvements in treatment and care

Adding cell-based vaccine to liver cancer therapy can slow cancer progression

Dendritic Cell Therapy Offers No Survival Advantage in Pleural Mesothelioma

Rural-urban disparities seen in cervical cancer

The Risk of Major Mortality is Associated with the Start of Opioids in Dementia.

Charles III, King of Kings, is Cancerous.

Recommended Articles For You

Everything You Need to Know About the Latest Hyponatremia Algorithm  

Understanding Hemosiderosis: Causes, Symptoms, and Treatment Options 

Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy  

All You Need To Know About Melanoma Maligna: Causes, Symptoms & Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Recent Rise in Early-Onset Solid Tumors Is Associated with Accelerated Aging.

2.

Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.

3.

A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.

4.

Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.

5.

Pancreatic cancer RNA vaccine shows durable T cell immunity

1.

Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation

2.

Understanding Hidrocystoma: Symptoms, Causes, and Treatment Options 

3.

KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer

4.

Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments

5.

The Science Behind Thrombolytic Drugs and Their Benefits 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

4.

Cost Burden/ Burden of Hospitalization For R/R ALL Patients

5.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot